XM无法为美国居民提供服务。
R
R

Roche


市场新闻

Assa Abloy, Kering, L'Oréal

EUROPE RESEARCH ROUNDUP-Assa Abloy, Kering, L'Oréal Oct 24 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Assa Abloy, Kering and L'Oréal, on Thursday. HIGHLIGHTS * Assa Abloy ASSAb.ST : Deutsche Bank raises target price to SEK 305 from SEK 300 * Barratt Redrow Plc BTRW.L : Morgan Stanley cuts target price to 580p from 600p * Dowlais Group Plc DWL.L : Citigroup raises to neutral from sell * Kering PRTP.PA : JP Morgan cuts target
B
D
D
D
E
E
H
H
K
K
L
L
P
R
R
R
S
S
S
S
S
T
Z
A
A
A
A
A
E
S

Roche comes out against allowing takeover of drug manufacturer Catalent

UPDATE 5-Roche comes out against allowing takeover of drug manufacturer Catalent Adds comment from Novo Holdings in paragraph 13 Roche CEO: not good to limit competition in this space Roche says not itself, but others affected by Catalent deal Swiss drugmaker joins US peer Lilly in voicing opposition Eli Lilly and advocacy groups also voice concerns over the deal Novo Nordisk and Catalent defend the acquisition, citing ample competition By Ludwig Burger FRANKFURT, Oct 23 (Reuters) - The CEO of p
A
A
P
R

Europe struggles for direction, earnings mixed

LIVE MARKETS-Europe struggles for direction, earnings mixed STOXX 600 flat Deutsche Bank, L'Oreal fall after earnings Wall St futures lower Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com EUROPE STRUGGLES FOR DIRECTION, EARNINGS MIXED European equities are mixed on Wednesday, after several corporate reports, with markets remaining on edge as the U.S.
D
I
L
L
R
S
V
S
E
F
U
G

Roche CEO comes out against approving takeover of drug manufacturer Catalent

Roche CEO comes out against approving takeover of drug manufacturer Catalent FRANKFURT, Oct 23 (Reuters) - The CEO of Swiss pharmaceuticals giant Roche ROG.S said competition authorities should not allow the controlling shareholder of Novo Nordisk NOVOb.CO to acquiring contract drug manufacturer Catalent CTLT.N . "It's not a problem for us, but it could be a problem for other smaller players, if there is a restriction in how many (contract manufacturers) are available.
R

Europe before the bell: futures dip after raft of earnings

LIVE MARKETS-Europe before the bell: futures dip after raft of earnings Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com EUROPE BEFORE THE BELL: FUTURES DIP AFTER RAFT OF EARNINGS European stock futures are edging lower in early trade after a large number of corporate earnings, with markets also watching rising yields and preparing for the upcoming U.S.
D
I
L
P
R
V
E
F
U
G

Roche CEO says more people have mpox in Europe than has been reported

UPDATE 1-Roche CEO says more people have mpox in Europe than has been reported Adds production capacity detail, background on mpox spread By Ludwig Burger FRANKFURT, Oct 23 (Reuters) - The CEO of Roche ROG.S said he has been informed that more cases of mpox infection have occurred in Europe than previously reported and that the Swiss group could quickly offer 10 times more test kits than are currently in demand.
R

Roche seen rising after Q3 sales beat

BUZZ-Roche seen rising after Q3 sales beat ** Shares in Roche ROG.S are indicated up 1.1% in Julius Baer premarket trade after the Swiss drugmaker reports better-than-expected Q3 sales ** "Reported 3Q24 Group sales beats consensus and our expectations," Vontobel says ** Key growth drivers such as multiple sclerosis drug Ocrevus, haemophilia shot Hemlibra and recently launched eye drug Vabysmo continue to perform above expectations, the brokerage highlights ** Analysts at J.P.
R
J

Roche CEO says more mpox cases likely to be reported in Europe

Roche CEO says more mpox cases likely to be reported in Europe FRANKFURT, Oct 23 (Reuters) - The CEO of Roche ROG.S said more cases of mpox infection have likely occurred in Europe than previously reported and that the group could quickly offer 10 times more test kits than are currently in demand. "It seems like there are more mpox cases already in Europe, maybe not all of them are in the media yet," CEO Thomas Schinecker said in a media call after the Swiss drugs and diagnostics company reporte
R

Roche Q3 sales advance by forex-adj 9%, beating market view

UPDATE 1-Roche Q3 sales advance by forex-adj 9%, beating market view Adds details on drugs, full-year guidance By Ludwig Burger FRANKFURT, Oct 23 (Reuters) - Roche 's ROG.S third-quarter sales gained a currency-adjusted 9% , beating market expectations, on higher prescriptions of once-monthly haemophilia shot Hemlibra and recently launched eye drug Vabysmo.
R

Roche Q3 sales advance by forex-adj 9%, beating market view

Roche Q3 sales advance by forex-adj 9%, beating market view FRANKFURT, Oct 23 (Reuters) - Roche ROG.S on Wednesday said that third-quarter sales gained a currency-adjusted 9% to 15.14 billion Swiss francs ($17.46 billion). That surpassed an analysts' consensus estimate of 14.9 billion francs, based on LSEG data. ($1 = 0.8671 Swiss francs) Reporting
R

FDA approves Astellas' gastric cancer therapy

UPDATE 4-FDA approves Astellas' gastric cancer therapy Adds pricing and availability in paragraph 4 By Sriparna Roy Oct 18 (Reuters) - The U.S. Food and Drug Administration approved Astellas' 4503.T therapy to treat a type of gastric cancer, the health regulator's website showed on Friday. The therapy, branded as Vyloy, was approved to be used in combination with a type of chemotherapy for patients with a type of cancer which begins in the gastroesophageal junction, where the esophagus and stoma
A
R

Japan corporate earnings week ahead

DIARY-Japan corporate earnings week ahead Oct 18 (Reuters) - Diary of Japan (.N225) corporate earnings for the week ahead JAPAN EARNINGS Start Date Start Time(GMT) RIC Company Name Event Name 23-Oct-2024 06:15 6594.T Nidec Corp Q2 2025 Nidec Corp Earnings Release 24-Oct-2024 06:00 7751.T Canon Inc Q3 2024 Canon Inc Earnings Release 25-Oct-2024 08:00 4519.T Chugai Pharmaceutical Co Ltd Q3 2024 Chugai Pharmaceutical Co Ltd Earnings Release 25-Oct-2024 06:00 6954.T Fanuc Corp Q2 2025 Fanuc Corp Ear
R
J

Consumer groups ask FTC to block Novo Holdings-Catalent deal

UPDATE 7-Consumer groups ask FTC to block Novo Holdings-Catalent deal Consumer groups and unions express competition concerns to FTC Deal could limit options for competitors developing GLP-1 drugs Concerns also raised about impact on gene therapy manufacturing Adds Novo Holdings comment in paragraph 7 By Jody Godoy and Maggie Fick NEW YORK, Oct 18 (Reuters) - U.S.
A
A
N
N
P
R

Consumer groups ask FTC to block Novo Holdings-Catalent deal

Consumer groups ask FTC to block Novo Holdings-Catalent deal Consumer groups and unions express competition concerns to FTC Deal could limit options for competitors developing GLP-1 drugs Concerns also raised about impact on gene therapy manufacturing By Jody Godoy, Maggie Fick NEW YORK, Oct 17 (Reuters) - Five U.S. consumer groups and two large labor unions urged the U.S.
A
A
N
N
P
R

Roche and Novartis topple Nestle in tight race

LIVE MARKETS-Roche and Novartis topple Nestle in tight race STOXX 600 up 0.6% TSMC beat, earnings provide support ECB in focus Banks lead gainers Nasdaq futures rise Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com ROCHE AND NOVARTIS TOPPLE NESTLE IN TIGHT RACE There is a tight race quietly unfolding in Zurich.
N
N
R
A
E
F
S
U
G

Swiss trade surplus at CHF 4.946 bln in September

TABLE-Swiss trade surplus at CHF 4.946 bln in September Oct 17 (Reuters) - Switzerland ran a merchandise trade surplus of 4.946 billion Swiss francs in September, the Federal Customs Office said on Thursday. KEY FIGURES (millions of Swiss francs) September 2024 August 2024 Imports 17.579 15.905 Exports 22.526 20.649 Balance 4.946 4.744 The figures exclude precious metals and stones, works of art and antiques.
C
L
N
R
R
S

Roche Holding Publishes Data Regarding Evrysdi Efficacy

BRIEF-Roche Holding Publishes Data Regarding Evrysdi Efficacy Oct 14 (Reuters) - ROCHE HOLDING AG ROG.S : POSITIVE DATA CONFIRM EVRYSDI EFFICACY AND SAFETY IN CHILDREN FIRST TREATED PRE-SYMPTOMATICALLY BEFORE 6 WEEKS OF AGE, WITH MOST ACHIEVING MOTOR MILESTONES SIMILAR TO CHILDREN WITHOUT SMA Source text for Eikon: ID:nBw92GX3Ja Further company cov
R

Roche Receives FDA Approval For Itovebi

BRIEF-Roche Receives FDA Approval For Itovebi Oct 11 (Reuters) - ROCHE HOLDING AG ROG.S : FDA APPROVES ROCHE’S ITOVEBI, A TARGETED TREATMENT FOR ADVANCED HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER WITH A PIK3CA MUTATION ROCHE HOLDING AG - ITOVEBI REGIMEN DOUBLES PROGRESSION-FREE SURVIVAL IN PHASE III STUDY ROCHE HOLDING AG - ITOVEBI R
R

FDA Approves Inavolisib With Palbociclib & Fulvestrant For Endocrine-Resistant,Pik3ca-Mutated,Hr-Positive,Her2-Negative,Advanced Breast Cancer

BRIEF-FDA Approves Inavolisib With Palbociclib & Fulvestrant For Endocrine-Resistant,Pik3ca-Mutated,Hr-Positive,Her2-Negative,Advanced Breast Cancer Oct 10 (Reuters) - FDA: FDA APPROVES INAVOLISIB WITH PALBOCICLIB AND FULVESTRANT FOR ENDOCRINE-RESISTANT, PIK3CA-MUTATED, HR-POSITIVE, HER2-NEGATIVE, ADVANCED BREAST CANCER FDA: APPROVED FOUNDATIONONE
R

Tempest Therapeutics jumps on agreement with Roche to advance liver cancer drug study

BUZZ-Tempest Therapeutics jumps on agreement with Roche to advance liver cancer drug study ** Shares of drug developer Tempest Therapeutics TPST.O up 19.21% at $1.60 premarket ** TPST to conduct a late-stage study of its experimental drug amezalpat, in combination with Swiss drugmaker Roche's ROG.S Tecentriq and bevacizumab, for the treatment of me
R



商品详情

热门商品

免责声明: XM Group仅提供在线交易平台的执行服务和访问权限,并允许个人查看和/或使用网站或网站所提供的内容,但无意进行任何更改或扩展,也不会更改或扩展其服务和访问权限。所有访问和使用权限,将受下列条款与条例约束:(i) 条款与条例;(ii) 风险提示;以及(iii) 完整免责声明。请注意,网站所提供的所有讯息,仅限一般资讯用途。此外,XM所有在线交易平台的内容并不构成,也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。

所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。

本网站上由XM和第三方供应商所提供的所有内容,包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接,皆保持不变,并作为一般市场评论所提供,而非投资性建议。所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为适用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解,XM非独立投资研究提示和风险提示相关资讯,更多详情请点击 这里

风险提示: 您的资金存在风险。杠杆商品并不适合所有客户。请详细阅读我们的风险声明